The Redwood City, CA-based company said it would acquire Bellwether Bio, which is focused on improving oncology patient care through pioneering research into the epigenomic content of cell free DNA.
The shift toward value-based care has changed the radiology game for both the providers and the companies making new imaging technology.
XSurgical is developing a remote-controlled surgical robot that could potentially be deployed in situations of disaster recovery, battlefields, and space.
WeHealth and PathMaker Neurosystems have formed an alliance to develop the first neuromodulation technology to treat spasticity.
Against the odds, Zimmer Biomet is the first company to gain FDA clearance for brain, spine, and knee offerings on one robotic platform.
Manufacturers should work to fill gaps in their portfolios to master disease management rather than focusing solely on one particular device category.
Prior to the acquisition, Brainlab had been an investor and distribution partner for Medineering for nearly three years.
Data from the UK’s National Health Service EndoBarrier Service show a significant reduction in HbA1c, weight, liver fat, and cardiovascular disease risks as well as a reduction in the need for insulin in some patients.
Alcon paid $285 million to acquire PowerVision, a company developing fluid-based intraocular lens implants.
The Abbott Park, IL-based company’s expanded indication would allow the MitraClip to address the secondary form of mitral regurgitation and would significantly increase the amount of people with MR able to be treated by the device.
The Kalamazoo, MI-based company is expected to pay $110 million up front, plus an additional $110 million in milestones to pick up OrthoSpace.
A new technology can diagnose a suspicious lesion in breast tissue in a third of a second, Dune Medical Devices reported.